Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977423 | 1.00 | DRD2 (0.48) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL224930 | 0.86 | EPHX1 (0.51) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL11921121 | 0.86 | EPHX1 (0.51) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL224929 | 0.86 | EPHX1 (0.51) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL2975555 | 0.85 | BTK (0.47) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL2975553 | 0.85 | BTK (0.47) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL2975551 | 0.85 | BTK (0.47) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL2975559 | 0.85 | BTK (0.47) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL2976522 | 0.85 | BTK (0.47) | DRD2EPHX1BTKDRD3KDM1A | |
| SCHEMBL2975557 | 0.85 | BTK (0.47) | DRD2EPHX1BTKDRD3KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767854-B2 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1884510-A1 | N-SUBSTITUTED PHENYLACETAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | HRH4, HRH2, CNR2 | DRD2 1323/4885EPHX1 1687/4885BTK 2590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.